AG真人官方

STOCK TITAN

Dyne Therapeutics, Inc. SEC Filings

DYN NASDAQ

Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking a clinical-stage biotech can feel like decoding lab notes. Dyne Therapeutics鈥� SEC filings stretch across technical 10-Ks, rapid-fire 8-Ks on trial milestones, and daily Form 4 insider trades. Finding cash-runway details or deciphering collaboration clauses shouldn鈥檛 slow your research.

Stock Titan solves this problem. Our AI reads every Dyne Therapeutics document the moment it hits EDGAR, then delivers plain-English briefs so you can instantly answer questions such as 鈥渦nderstanding Dyne Therapeutics SEC documents with AI鈥� or 鈥淒yne Therapeutics insider trading Form 4 transactions.鈥� Whether you need the latest Dyne Therapeutics quarterly earnings report 10-Q filing or a Dyne Therapeutics 8-K material events explained, the platform keeps you current.

  • 10-K  Annual Report 鈥� Cash runway, R&D spend, and FORCE platform risks, with Dyne Therapeutics annual report 10-K simplified for quick review.
  • 10-Q  Quarterly Update 鈥� Revenue, expenses, and trial progress in a Dyne Therapeutics earnings report filing analysis.
  • 8-K  Material Events 鈥� AG真人官方-time alerts on clinical data releases and financing rounds.
  • Form 4 鈥� Dyne Therapeutics Form 4 insider transactions real-time so you can track executive stock transactions before the market reacts.
  • DEF 14A Proxy 鈥� Dyne Therapeutics proxy statement executive compensation distilled into clear metrics.

Every filing includes AI-powered summaries, keyword search, and side-by-side comparisons so you can monitor trial timelines, segment expenses, and 鈥淒yne Therapeutics SEC filings explained simply鈥� without wading through hundreds of pages.

Rhea-AI Summary

Bitcoin Depot Inc. (Nasdaq: BTM) has filed a shelf registration statement on Form 424B5 allowing it to issue up to $100 million in securities, including Class A common stock, preferred stock, warrants and/or units, in one or more offerings. Specific terms, pricing and underwriters will be disclosed in future prospectus supplements.

Capital structure & potential dilution: The company currently has 22,555,710 Class A shares outstanding, 41,193,024 Class M shares (10 votes per share) controlled by the CEO, and 43,848,750 warrants exercisable at $11.50 until June 30 2033. Any issuance under the shelf could materially increase the public float and dilute existing holders, though proceeds will fund 鈥済eneral corporate purposes.鈥�

Business snapshot: Bitcoin Depot operates the largest Bitcoin ATM (BTM) network in North America with 8,483 kiosks and BDCheckout access in 10,926 retail locations as of March 31 2025. Q1 2025 revenue was $164.2 million, up from $138.5 million in Q1 2024, yet the company notes a 9.7 % revenue decline on a trailing-twelve-month basis despite a 15.7 % rise in Bitcoin prices, underscoring limited correlation between revenue and crypto price movements.

Key relationships & competitive position: The firm is the exclusive BTM provider for approximately 900 U.S. and Canadian Circle K stores and also licenses its BitAccess processing software to third-party operators, generating recurring software revenue.

Risk highlights (summarised from filing):

  • High dilution risk from additional equity or equity-linked issuances.
  • Complex, multi-class share structure with super-voting Class M and Class V shares.
  • Regulatory, competitive and litigation uncertainties outlined under 鈥淩isk Factors.鈥�
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
-
Rhea-AI Summary

Form 4 filed 07/01/2025: Atlassian Corporation (TEAM) Co-Founder, CEO, Director and 10% owner Michael Cannon-Brookes converted 490,560 Class B shares into Class A shares (Transaction Code C). The Class B shares were held by CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust. The conversion was executed in connection with sales to be effected under a Rule 10b5-1 trading plan adopted on 02/20/2025.

Following the transaction, Cannon-Brookes鈥� reported holdings are:

  • Class A common stock: 490,560 shares (indirect)
  • Class B common stock (convertible one-for-one with no expiration): 48,024,933 shares (indirect)

No price was paid for the conversion (exercise price $0.00). The filing signals preparation for future open-market sales while complying with Section 16 reporting obligations and the updated Rule 10b5-1 affirmative-defense conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Morgan Stanley Finance LLC, guaranteed by Morgan Stanley (NYSE: MS), is marketing 鈥淲orst-of RTY & SPX Callable Jump Notes鈥� maturing 5 Aug 2030. The notes are linked to the Russell 2000 (RTY) and the S&P 500 (SPX) and offer 100 % participation in any positive performance of the worst-performing index, subject to the issuer鈥檚 right to call.

Early-redemption mechanism: starting 5 Aug 2026 and monthly thereafter (48 dates), the issuer will call the notes if a proprietary risk-neutral model indicates it is economic to do so. Investors receive a fixed 鈥渏ump鈥� payment that begins at $1,120 (12 % over par) and rises by $10 every month to $1,590 (59 % over par) by July 2030.

At maturity (if never called) investors receive: 鈥� par plus 100 % upside on the worst performer, capped only by the 59 % maximum shown in the hypothetical table; 鈥� full principal protection鈥攅ven if either index falls 100 %, payment is still $1,000. The notes pay no periodic coupons.

Key economics: issue price $1,000; estimated value $961.40 (approximately 3.9 % below par, reflecting structuring and hedging costs). CUSIP 61778NDQ1. The securities will not be exchange-listed; liquidity will depend on Morgan Stanley鈥檚 secondary market.

Principal risks detailed in the FWP include: call risk (upside cut off), no interest income, credit risk of Morgan Stanley, small-cap exposure via RTY, and potential adverse pricing in secondary trading. Investors should consult the full preliminary pricing supplement and tax discussion before investing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
Rhea-AI Summary

Classover Holdings, Inc. (KIDZW) has called a virtual special meeting for July 18, 2025 to seek stockholder approval for two pivotal capital-structure actions.

Proposal 1 鈥� 鈥淣asdaq Proposal鈥�: authorizes the issuance of Class B common stock above the 19.99% threshold required by Nasdaq rules in connection with (i) a $400 million Equity Purchase Facility Agreement (EPFA) with Solana Strategic Holdings LLC and (ii) up to $500 million of senior secured convertible notes under a May 30, 2025 Securities Purchase Agreement. Both agreements allow issuance below the Nasdaq 鈥淢inimum Price鈥� and could trigger a change of control, hence the need for shareholder consent.

Proposal 2 鈥� 鈥淎uthorized Share Proposal鈥�: amends the certificate of incorporation to raise authorized Class B shares from 450 million to 2 billion. The board says the additional capacity will (1) cover all shares issuable under the EPFA and note conversions and (2) support future financing, equity compensation and strategic M&A.

Voting dynamics: CEO & Chair Hui Luo owns all 6.54 million Class A shares (25 votes each) plus 522.8 k Class B shares, giving management roughly 91% of total voting power. A Voting Agreement obligates Luo to vote 鈥淔OR鈥� both items, effectively guaranteeing passage.

Capital & structural implications:

  • The EPFA allows discounted share sales at 95% of the lowest VWAP over the prior three trading days, incentivising rapid resale by the investor.
  • The notes are senior, secured by all company assets (including crypto holdings) and prohibit cash dividends while outstanding.
  • If approved, common shareholders face potentially massive dilution and a decline in per-share voting and economic interests.

Strategic rationale & risks: Proceeds back a 鈥淪olana-centric鈥� digital-asset treasury strategy that includes buying, staking and validator operations. The proxy enumerates extensive risks: crypto price volatility, potential classification of SOL as a security, 1940 Act 鈥渋nvestment company鈥� issues, custody & cyber-security exposure, restrictive debt covenants and dilution. Failure to obtain approval would cap issuances at 19.99%, limit access to capital, and force repeated shareholder meetings.

Board recommendation: vote FOR both proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Dyne Therapeutics (DYN)?

The current stock price of Dyne Therapeutics (DYN) is $8.68 as of July 1, 2025.

What is the market cap of Dyne Therapeutics (DYN)?

The market cap of Dyne Therapeutics (DYN) is approximately 1.2B.

What is the core focus of Dyne Therapeutics?

Dyne Therapeutics is focused on developing innovative therapeutics for genetically driven neuromuscular diseases using its proprietary FORCE platform.

How does the FORCE platform work?

The FORCE platform utilizes a modular design that links a therapeutic payload with a targeted antibody fragment to ensure effective delivery to muscle tissue and the central nervous system.

Which neuromuscular conditions does the company target?

The company targets conditions such as myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and is also exploring therapies for facioscapulohumeral muscular dystrophy (FSHD) and other rare muscle diseases.

What makes Dyne Therapeutics unique in its industry?

Its unique advantage lies in the innovative FORCE platform that overcomes delivery challenges in muscle tissue, combined with a deep scientific expertise and a robust pipeline focused on serious neuromuscular diseases.

How does Dyne Therapeutics generate value?

The company builds value through its research and development of targeted, molecular therapies that potentially modify the progression of debilitating muscle diseases, addressing a high unmet medical need.

What is the importance of targeted drug delivery in their approach?

Targeted drug delivery is crucial because it enhances the efficacy and safety of the therapeutic candidates by ensuring that active compounds reach affected tissues, such as skeletal muscle and the CNS, directly.

How does Dyne Therapeutics position itself within the competitive landscape?

It distinguishes itself through a focused, science-driven approach that combines innovative technology, a diverse pipeline, and rigorous clinical investigation, making it a key player in the field of neuromuscular therapeutics.
Dyne Therapeutics, Inc.

NASDAQ:DYN

DYN Rankings

DYN Stock Data

1.21B
108.11M
0.69%
100.83%
10.31%
Biotechnology
Pharmaceutical Preparations
United States
WALTHAM